^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AT1412

    i
    Other names: AT1412
    Associations

    News

    Trials
    Company:
    AIMM Therap
    Drug class:
    CD9 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    [VIRTUAL] AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection (ESMO 2020)
    In a second melanoma model carrying a PD-1 resistant and highly aggressive tumour (SK-MEL5) AT1412 together with nivolumab was inducing full tumour rejection, while either one of the antibodies alone did not. Legal entity responsible for the study: The authors. Funding: AIMM Therapeutics.
    Clinical
    |
    CD8 (cluster of differentiation 8) • CD9 (CD9 Molecule)
    |
    Opdivo (nivolumab) • AT1412